ERBB2 and malignant colon neoplasm: In addition, treatment of colon cancer cells with trastuzumab plus T-DM1 showed a synergistic effect, with a stronger inhibitory effect than that of T-DM1 alone, especially LS174T cells, which showed high HER2 expression and had better sensitivity.